Literature DB >> 10405935

Extrarenal disease activity in systemic lupus erythematosus is not suppressed by chronic renal insufficiency or renal replacement therapy.

I N Bruce1, D C Hallett, D D Gladman, M B Urowitz.   

Abstract

OBJECTIVE: To assess whether chronic renal impairment (CRI) and/or renal replacement therapy (RRT) in systemic lupus erythematosus (SLE) are associated with reduced extrarenal SLE activity.
METHODS: This was a retrospective cohort analysis of patients with SLE who are followed at the University of Toronto Lupus Clinic. Patients with SLE were studied in 2 stages; chronic renal insufficiency (defined as a serum creatinine > 200 mumol/1 for > 6 months) and following the institution of dialysis therapy. Controls consisted of the next 2 age and sex matched patients in the clinic with a history of lupus nephritis who had not developed renal insufficiency. We assessed the flare rate (an increase in nonrenal SLEDAI > or = 1.0) for patients and controls in the first 12 months of followup at the clinic in each stage.
RESULTS: Twenty-one patients, 17 female and 4 male, were followed through 25 episodes of CRI or RRT as were 50 controls. In the CRI stage (n = 12), flares occurred in 8 (67%) within one year compared to 14 (58%) of 24 controls (p = NS). In the RRT stage (n = 13), flares occurred in 7 (54%) compared to 16 (62%) of 26 controls (p = NS). The magnitude as well as the characteristics of the flares did not differ between patients and controls in either stage.
CONCLUSION: Patients with SLE who develop CRI, or who receive RRT, continue to display evidence of ongoing extrarenal disease activity. Such patients require careful longterm followup for management of their extrarenal disease.

Entities:  

Mesh:

Year:  1999        PMID: 10405935

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  6 in total

1.  End-stage renal disease as the presenting manifestation of renal systemic lupus erythematosus.

Authors:  Lavjay Butani
Journal:  Pediatr Nephrol       Date:  2006-09-15       Impact factor: 3.714

Review 2.  Improving outcomes in patients with lupus and end-stage renal disease.

Authors:  Antonio Inda-Filho; Joel Neugarten; Chaim Putterman; Anna Broder
Journal:  Semin Dial       Date:  2013-09-04       Impact factor: 3.455

3.  Undertreatment of disease activity in systemic lupus erythematosus patients with endstage renal failure is associated with increased all-cause mortality.

Authors:  Anna Broder; Saakshi Khattri; Ruchika Patel; Chaim Putterman
Journal:  J Rheumatol       Date:  2011-09-01       Impact factor: 4.666

Review 4.  Disease activity in systemic lupus erythematosus patients with end-stage renal disease: systematic review of the literature.

Authors:  Patrícia Mattos; Mittermayer B Santiago
Journal:  Clin Rheumatol       Date:  2012-03-14       Impact factor: 2.980

5.  Prescribing Patterns of Hydroxychloroquine and Glucocorticoids Among Lupus Patients After New-Onset End-Stage Renal Disease.

Authors:  Anna Broder; Wenzhu B Mowrey; Ana Valle; Mimi Kim; Candace H Feldman; Kazuki Yoshida; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2021-06-13       Impact factor: 5.178

6.  Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.

Authors:  Maria Salgado Guerrero; Alejandra Londono Jimenez; Chrisanna Dobrowolski; Wenzhu B Mowrey; Beatrice Goilav; Shudan Wang; Anna Broder
Journal:  BMC Nephrol       Date:  2020-10-28       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.